Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Kelley Cotter has received funding from the National Science Foundation. Chinese tech giant ByteDance finalized its agreement to sell a majority stake in its video platform TikTok to a group of U.S.

You’re at the checkout screen after an online shopping spree, ready to enter your credit card number. You type it in and instantly see a red error message ...

Do you remember the early days of social media? The promise of connection, of democratic empowerment, of barriers crumbling and gates opening? In those heady days, the co-founder of Twitter said that ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Follow 24/7 Wall St. on Google By Joey Frenette Published ...

Ever wondered how social media platforms decide how to fill our feeds? They use algorithms, of course, but how do these algorithms work? A series of corporate leaks over the past few years provides a ...